Sustain Drug Release Company UroGen Submits New Drug Application to FDA


Brief

Sustain Drug Release Company UroGen Submits New Drug Application to FDA

Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections

Amir Rosenbaum 13:1812.07.18

UroGen Pharma Ltd., an Israel-based company developing a gel for the sustained release of drugs, announced Wednesday it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration. Nasdaq-listed UroGen, which focuses mainly on cancer treatment and urinary tract infections, submitted the application for the treatment of patients with low-grade non-muscle invasive bladder cancer, and if accepted, intends to start an advanced clinical trial in the U.S. in the third quarter of 2018.

 

UroGen raised $58 million when it listed on Nasdaq in May 2017, at a post-IPO company value of $155 million. Kite Pharma founder Arie Belldegrun sits as UroGel’s chairman of the board and is also an investor.

 

UroGen is currently trending down.

 

UroGen CEO Ron Bentsur. Photo: Tomeriqo UroGen CEO Ron Bentsur. Photo: Tomeriqo

 



Source link

Leave a Reply

Your email address will not be published.